Ann: Presentation: Phase 2 study of SNT-5505 in myelofibrosis, page-10

"Our primary focus will be on improvements in the TSS, as we know this is highly valued by regulators, clinicians and patients"

"Our conversations with key opinion leaders in myelofibrosis indicated that they would like to see 20% for SVR35 and 30% TSS50 as the benchmark for a ‘good result’ in this patient population"

• Substantial symptom relief observed over time:

At Week 12 – 46% (6/13) of evaluable patients3 achieved a ≥50% reduction in Myelofibrosis Symptom Assessment Form Total Symptom Score (TSS50), a benchmark for clinical response recognised by regulatory authorities such as the FDA.

At Week 38 – 80% (4/5) of evaluable patients achieved a TSS50.

It doesn't get much better than this in terms of early data. The longer they took SNT-5505, the better these patients are getting.